[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600057":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":31,"collaborators":35,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":19,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"University of Rochester","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Boys (0-3) of age diagnosed with DMD via new born screening",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Kimberly A Hart, MA","CONTACT","585-275-3767","Kim_Hart@urmc.rochester.edu",[18],{"facility":5,"status":19,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":10},"RECRUITING","Rochester","New York","14618","United States","US",{"type":26,"coordinates":27},"Point",[28,29],-77.61556,43.15478,{"lat":29,"lon":28},{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Bo Hoon Lee","Assistant professor of neurology",[36],{"name":37,"class":38},"United States Department of Defense","FED","100600057","the-baby-duchenne-study-characterizing-developmental-and-clinical-outcomes-in-the-first-three-years-in-children-with-duchenne-muscular-dystrophy-100600057",false,"NCT07092540","The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy","BABY DUCHENNE","Inclusion Criteria:\n\n* Male child between birth and 3.0 years of age at time of enrollment.\n* A confirmed and documented pathogenic or likely pathogenic variant in the DMD gene.\n* Ability of parent\u002Fguardian to understand and provide written informed consent (signing Parental Permission and Consent Form).\n* Willingness of parent\u002Fguardian to comply with the protocol Schedule of Activities, including all study site visits.\n\nExclusion Criteria:\n\n* Female\n* Presence of any confirmed genetic disease, other than DMD, that could impact early development, which, in the opinion of the PI, may confound interpretation of developmental progress.\n* Presence of any significant medical condition (i.e., extreme prematurity, hypoxic ischemic encephalopathy) which, in the opinion of the PI, may confound interpretation of the clinical course of DMD.\n* Inability\u002Funwillingness of parent\u002Fguardian to provide written permission (sign PPF) or to comply with the protocol Schedule of Activities.","MALE","0 Days","3 Years",{"count":50,"type":51},105,"ESTIMATED","OBSERVATIONAL","The aim of the BABY DUCHENNE study is to evaluate the natural history and characterize the early clinical outcomes in very young children (0-3 years) with Duchenne muscular dystrophy (DMD) identified by newborn screening programs.",[55],"Duchenne Muscular Dystrophy (DMD)",[57],"New born screening","2026-04-27",{"date":60,"type":61},"2026-05-04","ACTUAL",{"date":63,"type":51},"2026-05-30",{"date":65,"type":51},"2029-08-31",{"name":5,"class":6},1]